{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:22:35Z","timestamp":1742012555030,"version":"3.38.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T00:00:00Z","timestamp":1322265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10557-011-6355-z","type":"journal-article","created":{"date-parts":[[2011,11,25]],"date-time":"2011-11-25T04:48:15Z","timestamp":1322196495000},"page":"77-82","source":"Crossref","is-referenced-by-count":8,"title":["Anti-edematous Effects of Tolvaptan in Experimental Rodent Models"],"prefix":"10.1007","volume":"25","author":[{"given":"Toshiki","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ohmoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,26]]},"reference":[{"key":"6355_CR1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0025-7125(05)70540-X","volume":"81","author":"JP Morrison","year":"1997","unstructured":"Morrison JP. Edema and principles of diuretic use. Med Clin N Am. 1997;81:689\u2013704.","journal-title":"Med Clin N Am."},{"key":"6355_CR2","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273\u20138.","journal-title":"Am J Physiol Renal Physiol."},{"key":"6355_CR3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/B978-012635690-8\/50034-7","volume-title":"Diuretic agents\u2014clinical physiology and pharmacology","author":"BF Palmer","year":"1997","unstructured":"Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents\u2014clinical physiology and pharmacology. San Diego: Academic; 1997. p. 571\u201383."},{"key":"6355_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/B978-012635690-8\/50033-5","volume-title":"Diuretic agents\u2014clinical physiology and pharmacology","author":"A Rivera-Santos","year":"1997","unstructured":"Rivera-Santos A, Star R. Sodium: Volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents\u2014clinical physiology and pharmacology. San Diego: Academic Pressl; 1997. p. 559\u201369."},{"key":"6355_CR5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/356523a0","volume":"356","author":"A Morel","year":"1992","unstructured":"Morel A, O\u2019Carrol A, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992;356:523\u20136.","journal-title":"Nature"},{"key":"6355_CR6","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1016\/S0021-9258(17)41863-1","volume":"269","author":"M Thibonnier","year":"1994","unstructured":"Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994;269:3304\u201310.","journal-title":"J Biol Chem"},{"key":"6355_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-5793(94)01268-7","volume":"356","author":"Y Keyzer De","year":"1994","unstructured":"De Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of human V3 pituitary vasopressin receptor. FEBS Lett. 1994;356:215\u201320.","journal-title":"FEBS Lett"},{"key":"6355_CR8","doi-asserted-by":"crossref","first-page":"27088","DOI":"10.1016\/S0021-9258(18)47129-3","volume":"269","author":"T Sugimoto","year":"1994","unstructured":"Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem. 1994;269:27088\u201392.","journal-title":"J Biol Chem"},{"key":"6355_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/357333a0","volume":"357","author":"M Birnbaumer","year":"1992","unstructured":"Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333\u20135.","journal-title":"Nature"},{"key":"6355_CR10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/357336a0","volume":"357","author":"SJ Lolait","year":"1992","unstructured":"Lolait SJ, O\u2019Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992;357:336\u20139.","journal-title":"Nature"},{"key":"6355_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","volume":"29","author":"JG Verbalis","year":"2002","unstructured":"Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29:1\u20139.","journal-title":"J Mol Endocrinol"},{"key":"6355_CR12","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","volume":"7","author":"K Kondo","year":"1999","unstructured":"Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-metylbenzoyl-amino) benzoyl] -2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1999;7:1743\u201354.","journal-title":"Bioorg Med Chem"},{"key":"6355_CR13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"6355_CR14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","volume":"292","author":"T Hirano","year":"2000","unstructured":"Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288\u201394.","journal-title":"J Pharmacol Exp Ther"},{"key":"6355_CR15","first-page":"489","volume":"30","author":"S Inoue","year":"1996","unstructured":"Inoue S, Kido H, Hayashi K, Kubo Y, Uchida T, Watanabe M. Effects of a novel loop diuretic, torasemide, on several kinds of edematous models of rats. KISO TO RINSHO. 1996;30:489\u201396.","journal-title":"KISO TO RINSHO."},{"key":"6355_CR16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bcp.2007.11.011","volume":"75","author":"PT Veeraveedu","year":"2008","unstructured":"Veeraveedu PT, Watanabe K, Ma M, et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322\u201330.","journal-title":"Biochem Pharmacol"},{"key":"6355_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ki.1994.265","volume":"46","author":"Y Tsuboi","year":"1994","unstructured":"Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994;46:237\u201344.","journal-title":"Kidney Int"},{"key":"6355_CR18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0168-8278(03)00116-8","volume":"38","author":"G Fern\u00e1ndez-Varo","year":"2003","unstructured":"Fern\u00e1ndez-Varo G, Ros J, Cejudo-Mart\u00edn P, et al. Effect of the V1a\/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003;38:755\u201361.","journal-title":"J Hepatol"},{"key":"6355_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)38872-X","volume":"295","author":"W Jim\u00e9nez","year":"2000","unstructured":"Jim\u00e9nez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther. 2000;295:83\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"6355_CR20","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjp.0706375","volume":"146","author":"J Ros","year":"2005","unstructured":"Ros J, Fern\u00e1ndez-Varo G, Mu\u00f1oz-Luque J, et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br J Pharmacol. 2005;146:654\u201361.","journal-title":"Br J Pharmacol"},{"key":"6355_CR21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s10157-009-0196-0","volume":"13","author":"T Okada","year":"2009","unstructured":"Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol. 2009;13:438\u201346.","journal-title":"Clin Exp Nephrol"},{"key":"6355_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI109687","volume":"65","author":"D Chabardes","year":"1980","unstructured":"Chabardes D, Gagman-Brunette M, Imbert-Teboul M, et al. Adenylate cyclase responsiveness to hormones in various portions of the human nephron. J Clin Invest. 1980;65:439\u201348.","journal-title":"J Clin Invest"},{"key":"6355_CR23","first-page":"447","volume":"8","author":"D Chabardes","year":"1977","unstructured":"Chabardes D, Imbert-Teboul M, Gagnan-Brunette M, Morel F. Difference hormone target sites along the mouse and rabbit nephrons. Curr Probl Clin Biochem. 1977;8:447\u201354.","journal-title":"Curr Probl Clin Biochem"},{"key":"6355_CR24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1172\/JCI109917","volume":"66","author":"DA Hall","year":"1980","unstructured":"Hall DA, Varney DM. Effect of vasopressin electrical potential difference and chloride transport in mouse medullary thick ascending limb of Henle\u2019s loop. J Clin Invest. 1980;66:792\u2013802.","journal-title":"J Clin Invest"},{"key":"6355_CR25","first-page":"F159","volume":"240","author":"F Morel","year":"1981","unstructured":"Morel F. Sites of hormone action in the mammalian nephron. Am J Physiol. 1981;240:F159\u201364.","journal-title":"Am J Physiol"},{"key":"6355_CR26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jcem-60-5-914","volume":"60","author":"BT Ruggles","year":"1985","unstructured":"Ruggles BT, Murayama N, Werness JL, Gapstur SM, Bentley MD, Dousa TP. The vasopressin-sensitive adenylate cyclase in collecting tubules and in the thick ascending limbs of Henle\u2019s loop of human and canine kidney. J Clin Endocrinol Metab. 1985;60:914\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"6355_CR27","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963\u201371.","journal-title":"JAMA"},{"key":"6355_CR28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA."},{"key":"6355_CR29","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA."},{"key":"6355_CR30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/pmj.79.931.268","volume":"79","author":"LKM Bruyne De","year":"2003","unstructured":"De Bruyne LKM. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003;79:268\u201371.","journal-title":"Postgrad Med J."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-011-6355-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-011-6355-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-011-6355-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:18:29Z","timestamp":1741958309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-011-6355-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,26]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["6355"],"URL":"https:\/\/doi.org\/10.1007\/s10557-011-6355-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2011,11,26]]}}}